Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.
Vijay Kedia trims stake in Global Vectra in March quarter. Here’s how this smallcap stock has performed
Ace investor Vijay Kedia reduced his stake in Global Vectra Helicorp to 4.86% in Q4FY24. The move reflects profit-booking amid weakness in smallcap stocks. Despite
April 12, 2025